FC
HRTX icon

Financial Consulate’s Heron Therapeutics HRTX Stock Holding History

Financial Consulate’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$630 – 1398
2025
Q3 		$630 Buy
+500
New +$793 ﹤0.01% 941

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Financial Consulate's HRTX Position: Q4 2025 in Review

Financial Consulate sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 500 shares — an estimated $630 sold.

Financial Consulate first reported a position in HRTX in Q3 2025 and held it in 1 quarter. The position peaked at $630 in Q3 2025. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Financial Consulate reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Financial Consulate sold 500 Heron Therapeutics shares in Q4 2025, an estimated $630.
  • Financial Consulate first reported a position in Heron Therapeutics in Q3 2025 and held it in 1 quarter.
  • Financial Consulate's Heron Therapeutics position peaked at $630 in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Financial Consulate's 13F filing for Q4 2025, filed 22 Jan 2026.